These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 4937341)

  • 1. Effect of amantadine on some psychomotor performances in Parkinsonism. A double blind study.
    Laitinen LV; Vilkki J
    Ann Clin Res; 1971 Aug; 3(4):207-11. PubMed ID: 4937341
    [No Abstract]   [Full Text] [Related]  

  • 2. Amantadine hydrochloride in the treatment of Parkinsonism. A controlled trial.
    Appleton DB; Eadie MJ; Sutherland JM
    Med J Aust; 1970 Oct; 2(14):626-9. PubMed ID: 4920572
    [No Abstract]   [Full Text] [Related]  

  • 3. Double blind study using amantadine hydrochloride in the therapy of Parkinson's disease.
    Silver DE; Sahs AL
    Trans Am Neurol Assoc; 1971; 96():307-8. PubMed ID: 4945919
    [No Abstract]   [Full Text] [Related]  

  • 4. [Amantadine treatment in Parkinson's disease].
    Boman K; Kivalo E; Porras J
    Nord Med; 1970 Nov; 84(48):1518-20. PubMed ID: 4922228
    [No Abstract]   [Full Text] [Related]  

  • 5. [Amantadine therapy in Parkinsonism].
    Forssman B; Kihlstrand S; Larsson LE
    Lakartidningen; 1972 Mar; 69():55-9. PubMed ID: 4577428
    [No Abstract]   [Full Text] [Related]  

  • 6. A controlled study of the clinical effects of amantadine hydrochloride (Symmetrel).
    Merrick EM; Schmitt PP
    Curr Ther Res Clin Exp; 1973 Aug; 15(8):552-8. PubMed ID: 4200529
    [No Abstract]   [Full Text] [Related]  

  • 7. Controlled trial of amantadine hydrochloride in Parkinson's disease.
    Jorgensen PB; Bergin JD; Haas L; Cuningham JA; Morah DD; Pollock M; Robinson RG; Spears GF
    N Z Med J; 1971 May; 73(468):263-7. PubMed ID: 4932146
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapeutic experiences with amantadine sulfate as a monotherapeutic drug in patients with Parkinsonism].
    Völler GW; Deze J
    Z Allgemeinmed; 1973 May; 49(14):664-70. PubMed ID: 4585272
    [No Abstract]   [Full Text] [Related]  

  • 9. [Modification of Parkinson tremor by budipine. A comparative study with amantadine].
    Iizuka J; Fischer R
    Nervenarzt; 1986 Mar; 57(3):184-6. PubMed ID: 3515215
    [No Abstract]   [Full Text] [Related]  

  • 10. [The therapeutic effectiveness of amantadine (midantan) in parkinsonism syndromes].
    Kiseleva AM; Zlydnikov DM; Mazhinskaia VP; Lebedeva VK; Zakharova NG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(4):530-4. PubMed ID: 4705408
    [No Abstract]   [Full Text] [Related]  

  • 11. Amantadine HCL (Symmetrel) and its relation to Levo-Dopa in the treatment of Parkinson's disease.
    Schwab RS; England AC
    Trans Am Neurol Assoc; 1969; 94():85-90. PubMed ID: 4907453
    [No Abstract]   [Full Text] [Related]  

  • 12. [Amantadine and dexetimide in the treatment of parkinsonism].
    Hakkarainen H; Viukari M
    Duodecim; 1973 Jul; 89(21):1437-41. PubMed ID: 4586970
    [No Abstract]   [Full Text] [Related]  

  • 13. Amantadine in Parkinsonism. An extended prospective trial.
    Rao NS; Pearce J
    Practitioner; 1971 Feb; 206(232):241-5. PubMed ID: 4928964
    [No Abstract]   [Full Text] [Related]  

  • 14. Short-term effect of amantadine sulphate on motor performance and reaction time in patients with idiopathic Parkinson's disease.
    Pinter MM; Birk M; Helscher RJ; Binder H
    J Neural Transm (Vienna); 1999; 106(7-8):711-24. PubMed ID: 10907729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amantadine hydrochloride in the treatment of parkinsonism: a placebo-controlled double-blind study.
    Freedman BE; Getz E; MacGregor JM; Ames FR
    S Afr Med J; 1971 Apr; 45(16):435-7. PubMed ID: 4932339
    [No Abstract]   [Full Text] [Related]  

  • 16. Trial of amantadine in Parkinson's disease.
    Campbell AM; Williams MJ
    Br J Clin Pract; 1972 Jan; 26(1):19-22. PubMed ID: 4554563
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of ciladopa on Parkinson's disease: a preliminary report.
    Weiner WJ; Berger JR
    Adv Neurol; 1987; 45():583-6. PubMed ID: 3548268
    [No Abstract]   [Full Text] [Related]  

  • 18. [The influence of MIF (melanocyte-stimulating hormone-release inhibiting factor) on psychomotor function and mood in parkinsonian patients. Preliminary report (author's transl)].
    Schneider E; Fischer PA; Jacobi P; Reh W
    Arzneimittelforschung; 1978; 28(8):1296-7. PubMed ID: 37848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind corssover analyses.
    Fahn S; Isgreen WP
    Neurology; 1975 Aug; 25(8):695-700. PubMed ID: 807869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refinement in the measurement of treatment response with combined L-dopa and amantadine in Parkinsonism.
    Kravitz EA; Hollmann TD
    J Chronic Dis; 1974 Dec; 27(11-12):563-72. PubMed ID: 4612055
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.